希玛医疗近期回购情况, 回购日期回购均价回购股数回购金额本年累计回购股数2025-12-191.65918.20万30.20万3001.20万2025- 12-181.61832.00万51.78万2983.00万2025-12-021.75016.00万28.01万2951.00万2025-12-011.75013.20万 23.10万2935.00万2025-11-281.73322.00万38.13万2921.80万2025-11-271.73012.00万20.76万2899.80万 2025-11-261.73216.00万27.72万2887.80万2025-11-251.72020.00万34.41万2871.80万2025-11-241.71220.00 万34.24万2851.80万2025-11-211.74024.00万41.76万2831.80万2025-11-201.80612.00万21.67万2807.80万 2025-11-191.80220.00万36.04万2795.80万2025-11-181.79216.00万28.67万2775.80万2025-11-171.8086 ...

12月19日，歌礼制药-B回购20.00万股股票，每股回购均价12.79港元，共耗资约255.86万港元，本年累 计回购882.60万股，占总股本0.88%。 回购日期回购均价回购股数回购金额本年累计回购股数2025-12-1912.79320.00万255.86万882.60万2025- 12-1812.69320.00万253.86万862.60万2025-12-1713.00620.00万260.12万842.60万2025-12-1613.04920.00万 260.99万822.60万2025-12-1214.57930.00万437.38万802.60万2025-12-0412.925162.00万2093.89万772.60万 2025-12-0312.196130.60万1592.75万610.60万2025-11-059.24010.00万92.40万480.00万2025-10- 319.66320.00万193.27万470.00万2025-10-289.18910.00万91.89万450.00万2025-10-279.70010.00万97.00万 440.00万2025-10-23 ...

Core Viewpoint - Tsugami Machine Tool China has recently repurchased 80,000 shares at an average price of HKD 31.80 per share, totaling approximately HKD 2.5443 million, indicating management's confidence in the company's future and a strategy to enhance shareholder returns [1][2]. Group 1: Share Buyback Details - The company has repurchased a total of 9.86 million shares this year, accounting for 2.62% of its total share capital [1]. - The recent buyback on December 19 involved 80,000 shares, with a total expenditure of HKD 2.5443 million [1]. - The average repurchase prices for previous buybacks in December ranged from HKD 30.49 to HKD 34.40, showing a strategic approach to capital management [1]. Group 2: Company Overview - Tsugami Machine Tool China specializes in the research, development, manufacturing, and sales of precision machine tools, including CNC lathes and machining centers, primarily serving the automotive, electronics, and medical device sectors [2]. - The company is a subsidiary of the Japanese Tsugami Group and has leveraged its parent company's technological advantages to secure a market presence in China [2]. - Financially, the company has shown stable revenue and profit performance, although it is subject to fluctuations due to the cyclical nature of the manufacturing industry [2].

Group 1 - The company, MicroTech Medical-B, recently repurchased 28,000 shares at an average price of HKD 7.75 per share, totaling approximately HKD 217,100, with a cumulative repurchase of 1,033,000 shares this year, representing 0.62% of the total share capital [1] - The stock price of MicroTech Medical-B increased by 3.72% to HKD 7.80 per share at the close of the Hong Kong stock market [1] - The repurchase activity is seen as a signal of management's confidence in the company's long-term value and aims to stabilize market sentiment amid volatility in the healthcare sector [1] Group 2 - MicroTech Medical-B is an innovative company focused on diabetes management and high-end medical device development, headquartered in Hangzhou, China [2] - The company's core products include patch insulin pump systems and continuous glucose monitoring systems, providing intelligent solutions for diabetes patients [2] - MicroTech Medical-B was listed on the Hong Kong Stock Exchange in October 2021 and has been expanding its global market presence through technological innovation [2] - The company has a significantly higher R&D investment ratio compared to the industry average, indicating strong technological drive [2] - As a leading player in the diabetes management sector in China, its products have received CE certification in the EU and approval from China's NMPA, with business operations covering multiple regions including Asia and Europe [2]

Core Viewpoint - Miniso Group Holding Limited (09896) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company plans to repurchase 27,000 shares at a total cost of HKD 1.0206 million [1] - The buyback price per share ranges from HKD 37.6 to HKD 38 [1]

格隆汇12月19日丨华源控股(002787.SZ)公布，近日，公司取得中国工商银行股份有限公司苏州长三角 一体化示范区分行出具的《贷款承诺函》，主要内容如下：1、借款金额：不超过人民币5,400万元； 2、借款期限：3年；3、借款用途：仅为回购公司股票。 ...

中远海控(01919.HK)12月19日耗资5366.89万港元回购396.55万股 中远海控(01919.HK)12月18日耗资 8055.74万港元回购590万股 相关事件 格隆汇12月19日丨中远海控(01919.HK)发布公告，2025年12月19日耗资5366.89万港元回购396.55万股， 回购价格每股13.47-13.73港元。 ...

Group 1 - As of December 18, southbound funds hold approximately 454.5 million shares of Beike-W (2423.HK), accounting for 12.96% of its total share capital, with a market value of about HKD 19.008 billion [1] - Southbound funds have shown a strong increasing trend in their holdings of Beike, with net increases recorded on 10 out of the last 10 trading days and 18 out of the last 20 trading days, indicating a strong buying interest [1] - The continuous increase in holdings by southbound funds reflects a recognition of Beike's long-term investment value and liquidity, signaling a clear "buy and hold" message [1] Group 2 - Beike has been consistently favored by both international and domestic large financial institutions this year, with notable increases in holdings from major private equity firms [3] - The latest Q3 financial report from Beike shows year-on-year revenue growth, with profitable operations in home decoration and rental businesses, despite some short-term market headwinds [3] - Beike has announced an increase in its stock repurchase authorization from USD 3 billion to USD 5 billion, extending the repurchase plan until August 31, 2028, and has executed a record high buyback of USD 280 million in Q3 [3]

同道猎聘(06100)发布公告，于2025年12月19日该公司斥资141.7万港元回购35.42万股，回购价格为每股 3.99-4.03港元。 ...

Core Viewpoint - BBVA has announced a share buyback program amounting to 3.96 billion euros ($4.64 billion), marking the largest buyback in the bank's history [1] Company Summary - The share buyback reflects BBVA's strong financial position and commitment to returning value to shareholders [1] - This buyback program is significant in size, indicating the bank's confidence in its future performance and capital management strategy [1]